Eloxx Pharmaceuticals Inc (ELOX)

Currency in USD
18.760
-0.310(-1.63%)
Closed·
18.7600.000(0.00%)
·
ELOX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
17.17019.230
52 wk Range
0.00019.960
Key Statistics
Prev. Close
19.07
Open
19.23
Day's Range
17.17-19.23
52 wk Range
0-19.96
Volume
29.64K
Average Volume (3m)
49.23K
1-Year Change
99,999,999.9999%
Book Value / Share
11.5
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ELOX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
41.500
Upside
+121.22%
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with high price volatility

Eloxx Pharmaceuticals Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 41.500
(+121.22% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
LifeSci Capital
Buy40.00+113.22%-New CoverageJul 22, 2026
Guggenheim
Buy43.00+129.21%-New CoverageJul 20, 2026

Earnings

Latest Release
Aug 11, 2026
EPS / Forecast
-0,66 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ELOX Income Statement

Compare ELOX to Peers and Sector

Metrics to compare
ELOX
Peers
Sector
Relationship
P/E Ratio
−7.1x−0.3x−0.4x
PEG Ratio
-0.000.00
Price/Book
1.6x1.7x2.6x
Price / LTM Sales
-2.3x3.1x
Upside (Analyst Target)
121.2%381.4%47.8%
Fair Value Upside
Unlock9.5%6.2%Unlock

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations. It has collaboration with Almirall, S.A. to develop and commercialize ZKN-013, an oral ribosome modulating agent for the treatment of rare skin diseases, such as recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa with nonsense mutations. Eloxx Pharmaceuticals, Inc. was incorporated in 1999 and is based in Arlington, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
89,28K2,21%1,67M
Other Institutional Investors
4,22M97,79%79,08M
Public Companies & Retail Investors
0,000,00%0,00
Total
4,3M100,00%80,76M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Domicilium Capital Partners, LLC15,22%614 28511 524
EcoR1 Capital, LLC10,00%403 5867 571

FAQ

What Is the Eloxx Pharma (ELOX) Stock Price Today?

The Eloxx Pharma stock price today is 18,760 USD.

What Stock Exchange Does Eloxx Pharma Trade On?

Eloxx Pharma is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Eloxx Pharma?

The stock symbol for Eloxx Pharma is "ELOX."

What Is the Eloxx Pharma Market Cap?

As of today, Eloxx Pharma market cap is 76,980M USD.

What Is Eloxx Pharma's Earnings Per Share (TTM)?

The Eloxx Pharma EPS (TTM) is -2,849.

From a Technical Analysis Perspective, Is ELOX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Eloxx Pharma Stock Split?

Eloxx Pharma has split 4 times.

How Many Employees Does Eloxx Pharma Have?

Eloxx Pharma has 10 employees.

What is the current trading status of Eloxx Pharma (ELOX)?

As of Aug 15, 2026, Eloxx Pharma (ELOX) is trading at a price of 18,760 USD, with a previous close of 19,070 USD. The stock has fluctuated within a day range of 17,170 USD to 19,230 USD, while its 52-week range spans from 0,000 USD to 19,960 USD.

What Is Eloxx Pharma (ELOX) Price Target According to Analysts?

The average 12-month price target for Eloxx Pharma is 41,500 USD, with a high estimate of 43 USD and a low estimate of 40 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +121,22% Upside potential.

What Is the ELOX Premarket Price?

ELOX's last pre-market stock price is 19,600 USD. The pre-market share volume is 340,000, and the stock has decreased by 0,530, or 2,780%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.